Needham & Company LLC reaffirmed their buy rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a research report released on Tuesday, Benzinga reports. They currently have a $32.00 target price on the biopharmaceutical company’s stock. Several other brokerages have also issued reports on ACAD. HC Wainwright reissued a buy rating and issued […]
China Universal Asset Management Co. Ltd. increased its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 351.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 18,985 shares of the biopharmaceutical company’s stock after purchasing an additional 14,783 shares during the […]
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) reached a new 52-week low during trading on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $29.00 to $25.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. ACADIA Pharmaceuticals traded as low as $17.56 and last traded […]
ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its price objective trimmed by JPMorgan Chase & Co. from $29.00 to $25.00 in a research report report published on Monday, Benzinga reports. The brokerage currently has an overweight rating on the biopharmaceutical company’s stock. A number of other analysts also recently issued reports on the stock. JMP […]
Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) hit a new 52-week low during trading on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $29.00 to $25.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. ACADIA Pharmaceuticals traded as low as $17.56 and […]